Chinese General Practice ›› 2023, Vol. 26 ›› Issue (14): 1758-1765.DOI: 10.12114/j.issn.1007-9572.2022.0798
• Original Research • Previous Articles Next Articles
Received:
2022-08-10
Revised:
2022-12-15
Published:
2023-05-15
Online:
2023-01-18
Contact:
GUO Zhiguo
通讯作者:
郭治国
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0798
序号 | 性别 | 年龄(岁) | 既往史 | ||||||
---|---|---|---|---|---|---|---|---|---|
精神疾病 | 高血压 | 糖尿病 | 冠心病 | 陈旧脑梗死 | 肾病综合征 | 缺铁性贫血 | |||
1 | 男 | 29 | + | - | - | - | - | - | - |
2 | 女 | 26 | - | - | - | - | - | - | - |
3 | 男 | 39 | - | + | + | - | - | - | - |
4 | 男 | 56 | + | + | - | - | - | - | - |
5 | 男 | 64 | + | + | + | + | + | - | - |
6 | 男 | 74 | - | + | + | - | + | - | - |
7 | 男 | 39 | - | + | - | - | - | - | - |
8 | 女 | 26 | - | - | - | - | - | - | - |
9 | 男 | 23 | - | - | - | - | - | + | - |
10 | 女 | 43 | + | + | - | - | - | - | + |
11 | 男 | 19 | + | - | - | - | - | - | - |
Table 1 Demographic characteristics of patients
序号 | 性别 | 年龄(岁) | 既往史 | ||||||
---|---|---|---|---|---|---|---|---|---|
精神疾病 | 高血压 | 糖尿病 | 冠心病 | 陈旧脑梗死 | 肾病综合征 | 缺铁性贫血 | |||
1 | 男 | 29 | + | - | - | - | - | - | - |
2 | 女 | 26 | - | - | - | - | - | - | - |
3 | 男 | 39 | - | + | + | - | - | - | - |
4 | 男 | 56 | + | + | - | - | - | - | - |
5 | 男 | 64 | + | + | + | + | + | - | - |
6 | 男 | 74 | - | + | + | - | + | - | - |
7 | 男 | 39 | - | + | - | - | - | - | - |
8 | 女 | 26 | - | - | - | - | - | - | - |
9 | 男 | 23 | - | - | - | - | - | + | - |
10 | 女 | 43 | + | + | - | - | - | - | + |
11 | 男 | 19 | + | - | - | - | - | - | - |
序号 | 服药类型 | 服药剂量 | 同服药物或物质 | 过量服药至就诊间隔时间(h) | 超量药物血药浓度 |
---|---|---|---|---|---|
1 | 自服 | 苯磺酸左氨氯地平(2.5 mg)700片 | 无 | 9.33 | 氨氯地平890 μg/L |
2 | 自服 | 苯磺酸左氨氯地平(2.5 mg)35片,缬沙坦氨氯地平(80 mg/5 mg)28片 | 盐酸地芬尼多(25 mg)30片,卡托普利(12.5 mg)30~40片,茶苯海明(25 mg)20片,白酒250 ml | 6.5 | 氨氯地平219.7 μg/L,缬沙坦43.7 mg/L,地芬尼多3.1 mg/L,苯海拉明2.7 mg/L,卡托普利0.5 mg/L |
3 | 处方剂量 | 氨氯地平阿托伐他汀(5 mg/20 mg)共4片 | 氯沙坦氢氯噻嗪(50 mg/12.5 mg)4片,阿罗洛尔(10 mg)2片,红酒150 ml | 不能明确 | 氨氯地平26.9 μg/L,氯沙坦23.6 μg/L,阿托伐他汀32.5 μg/L,阿罗洛尔33.5 μg/L,乙醇146.6 mg/L |
4 | 自服 | 苯磺酸氨氯地平(5 mg)4片,苯磺酸左氨氯地平(2.5 mg)2片 | 奥美沙坦(20 mg)2片 | 1 | 氨氯地平35.7 μg/L |
5 | 自服 | 苯磺酸左氨氯地平(具体剂型不详)24片 | 佐匹克隆,剂型剂量不详 | 7 | 氨氯地平61 μg/L,佐匹克隆0.6 mg/L,美托洛尔1.2 mg/L |
6 | 误服 | 硝苯地平控释片(30 mg)7片 | 无 | 1 | 硝苯地平0.2 mg/L |
7 | 自服 | 硝苯地平控释片(具体剂型不详)100片,非洛地平(具体剂型不详)100片,马来酸左旋氨氯地平(具体剂型不详)20片 | 阿卡波糖(具体剂型不详)100片 | 10 | 氨氯地平39 μg/L,奥美沙坦0.8 mg/L,比索洛尔0.2 mg/L,二甲双胍5.4 mg/L |
8 | 自服 | 贝尼地平(8 mg)80片 | 无 | 0.5 | 贝尼地平108 μg/L |
9 | 自服 | 硝苯地平缓释片(20 mg)60片,苯磺酸氨氯地平(5 mg)10片 | 地高辛(0.25 mg)100片,卡托普利(12.5 mg)200片 | 3 | 硝苯地平1.1 mg/L,地高辛74 μg/L,卡托普利1.4 mg/L |
10 | 自服 | 维拉帕米(具体剂型不详)100片 | 美托洛尔(具体剂型不详)200片 | 1.5 | 维拉帕米1.5 mg/L,美托洛尔1.25 mg/L |
11 | 自服 | 硝苯地平(10 mg)200片 | 艾司唑仑(具体剂型不详),唑吡坦(具体剂型不详)共20余片,皮下注射门冬胰岛素约180 U | 1 | 硝苯地平4.8 mg/L,唑吡坦1.3 mg/L,艾司唑仑0.3 mg/L |
Table 2 The oral dose and maximum plasma concentration of calcium channel blockers in patients
序号 | 服药类型 | 服药剂量 | 同服药物或物质 | 过量服药至就诊间隔时间(h) | 超量药物血药浓度 |
---|---|---|---|---|---|
1 | 自服 | 苯磺酸左氨氯地平(2.5 mg)700片 | 无 | 9.33 | 氨氯地平890 μg/L |
2 | 自服 | 苯磺酸左氨氯地平(2.5 mg)35片,缬沙坦氨氯地平(80 mg/5 mg)28片 | 盐酸地芬尼多(25 mg)30片,卡托普利(12.5 mg)30~40片,茶苯海明(25 mg)20片,白酒250 ml | 6.5 | 氨氯地平219.7 μg/L,缬沙坦43.7 mg/L,地芬尼多3.1 mg/L,苯海拉明2.7 mg/L,卡托普利0.5 mg/L |
3 | 处方剂量 | 氨氯地平阿托伐他汀(5 mg/20 mg)共4片 | 氯沙坦氢氯噻嗪(50 mg/12.5 mg)4片,阿罗洛尔(10 mg)2片,红酒150 ml | 不能明确 | 氨氯地平26.9 μg/L,氯沙坦23.6 μg/L,阿托伐他汀32.5 μg/L,阿罗洛尔33.5 μg/L,乙醇146.6 mg/L |
4 | 自服 | 苯磺酸氨氯地平(5 mg)4片,苯磺酸左氨氯地平(2.5 mg)2片 | 奥美沙坦(20 mg)2片 | 1 | 氨氯地平35.7 μg/L |
5 | 自服 | 苯磺酸左氨氯地平(具体剂型不详)24片 | 佐匹克隆,剂型剂量不详 | 7 | 氨氯地平61 μg/L,佐匹克隆0.6 mg/L,美托洛尔1.2 mg/L |
6 | 误服 | 硝苯地平控释片(30 mg)7片 | 无 | 1 | 硝苯地平0.2 mg/L |
7 | 自服 | 硝苯地平控释片(具体剂型不详)100片,非洛地平(具体剂型不详)100片,马来酸左旋氨氯地平(具体剂型不详)20片 | 阿卡波糖(具体剂型不详)100片 | 10 | 氨氯地平39 μg/L,奥美沙坦0.8 mg/L,比索洛尔0.2 mg/L,二甲双胍5.4 mg/L |
8 | 自服 | 贝尼地平(8 mg)80片 | 无 | 0.5 | 贝尼地平108 μg/L |
9 | 自服 | 硝苯地平缓释片(20 mg)60片,苯磺酸氨氯地平(5 mg)10片 | 地高辛(0.25 mg)100片,卡托普利(12.5 mg)200片 | 3 | 硝苯地平1.1 mg/L,地高辛74 μg/L,卡托普利1.4 mg/L |
10 | 自服 | 维拉帕米(具体剂型不详)100片 | 美托洛尔(具体剂型不详)200片 | 1.5 | 维拉帕米1.5 mg/L,美托洛尔1.25 mg/L |
11 | 自服 | 硝苯地平(10 mg)200片 | 艾司唑仑(具体剂型不详),唑吡坦(具体剂型不详)共20余片,皮下注射门冬胰岛素约180 U | 1 | 硝苯地平4.8 mg/L,唑吡坦1.3 mg/L,艾司唑仑0.3 mg/L |
序号 | 临床表现 | |||||||
---|---|---|---|---|---|---|---|---|
休克 | 恶心呕吐 | 头晕 | 乏力 | 心率增快 | 心率减慢 | 晕厥 | 昏睡 | |
1 | + | - | - | - | + | - | - | - |
2 | + | + | + | + | - | - | - | - |
3 | + | - | + | - | - | - | + | - |
4 | - | - | - | - | - | - | - | - |
5 | + | - | - | + | - | - | - | - |
6 | - | - | - | - | - | - | - | - |
7 | + | + | + | + | - | + | - | - |
8 | + | + | - | - | + | - | - | - |
9 | + | + | + | - | - | - | - | - |
10 | + | + | - | - | - | + | - | + |
11 | + | - | - | - | + | - | - | - |
Table 3 Clinical manifestations of patients on arrival
序号 | 临床表现 | |||||||
---|---|---|---|---|---|---|---|---|
休克 | 恶心呕吐 | 头晕 | 乏力 | 心率增快 | 心率减慢 | 晕厥 | 昏睡 | |
1 | + | - | - | - | + | - | - | - |
2 | + | + | + | + | - | - | - | - |
3 | + | - | + | - | - | - | + | - |
4 | - | - | - | - | - | - | - | - |
5 | + | - | - | + | - | - | - | - |
6 | - | - | - | - | - | - | - | - |
7 | + | + | + | + | - | + | - | - |
8 | + | + | - | - | + | - | - | - |
9 | + | + | + | - | - | - | - | - |
10 | + | + | - | - | - | + | - | + |
11 | + | - | - | - | + | - | - | - |
序号 | 白细胞计数升高 | 乳酸升高 | 高血糖 | 急性肾功能不全 | 代谢性酸中毒 | 肌钙蛋白I升高 |
---|---|---|---|---|---|---|
1 | + | + | + | + | + | - |
2 | + | + | - | - | - | - |
3 | + | + | + | - | - | - |
4 | + | + | - | - | - | - |
5 | + | - | + | - | - | - |
6 | - | - | - | - | - | - |
7 | + | + | - | + | + | - |
8 | - | + | + | - | - | - |
9 | + | - | - | + | - | + |
10 | - | + | + | - | - | + |
11 | + | + | - | - | - | - |
Table 4 The abnormal results of patient's first laboratory test
序号 | 白细胞计数升高 | 乳酸升高 | 高血糖 | 急性肾功能不全 | 代谢性酸中毒 | 肌钙蛋白I升高 |
---|---|---|---|---|---|---|
1 | + | + | + | + | + | - |
2 | + | + | - | - | - | - |
3 | + | + | + | - | - | - |
4 | + | + | - | - | - | - |
5 | + | - | + | - | - | - |
6 | - | - | - | - | - | - |
7 | + | + | - | + | + | - |
8 | - | + | + | - | - | - |
9 | + | - | - | + | - | + |
10 | - | + | + | - | - | + |
11 | + | + | - | - | - | - |
化验 | 1号 | 7号 | 9号 | 10号 | |
---|---|---|---|---|---|
白细胞计数(×109/L) | 来诊 | 29.90 | 19.31 | 17.19 | 8.90 |
最差 | 29.90 | 19.31 | 35.49 | 30.14 | |
血小板计数(×109/L) | 来诊 | 199 | 485 | 539 | 333 |
最差 | 48 | 63 | 103 | 85 | |
肌酐(μmol/L) | 来诊 | 251 | 426 | 158 | 83 |
最差 | 364 | 426 | 259 | 233 | |
丙氨酸氨基转移酶(U/L) | 来诊 | 25 | 24 | 10 | 67 |
最差 | 250 | 5 350 | 323 | 71 | |
天冬氨酸氨基转移酶(U/L) | 来诊 | 33 | 28 | 23 | 61 |
最差 | 850 | 10 480 | 548 | 110 | |
总胆红素(μmol/L) | 来诊 | 8.8 | 9.4 | 15.5 | 10.4 |
最差 | 22.4 | 87.9 | 46.8 | 44.2 | |
肌钙蛋白I(μg/L) | 来诊 | <0.010 | <0.010 | 3.200 | 0.024 |
最差 | 3.200 | 12.000 | 19.000 | 0.032 | |
肌酸激酶(U/L) | 来诊 | 43 | 55 | 167 | 34 |
最差 | >16 000 | 13 934 | 24 101 | 2 242 | |
葡萄糖(mmol/L) | 来诊 | 15.4 | 5.6 | 8.1 | 24.0 |
最差 | 36.1 | 34.3 | 19.5 | 24.0 | |
pH值 | 来诊 | 7.32 | 7.05 | 7.53 | 7.48 |
最差 | 7.06 | 6.80 | 7.07 | 7.23 | |
脂肪酶(U/L) | 来诊 | 136 | 343 | 62 | 80 |
最差 | >2 000 | >2 000 | 929 | 431 | |
淀粉酶(U/L) | 来诊 | 89 | 70 | 135 | 57 |
最差 | 642 | 559 | 276 | 351 | |
凝血酶原时间(s) | 来诊 | 11.3 | 14.3 | 10.9 | 14.9 |
最差 | 12.9 | 未再测 | 15.0 | 15.4 | |
凝血酶原活动度(%) | 来诊 | 88 | 65 | 96 | 61 |
最差 | 67 | 未再测 | 51 | 59 | |
活化部分凝血活酶(s) | 来诊 | 26.6 | 31.6 | 34.5 | 100.7 |
最差 | 182.3 | 未再测 | 62.8 | 206.4 | |
纤维蛋白降解产物(mg/L) | 来诊 | <2.5 | <2.5 | <2.5 | 23.4 |
最差 | 6.1 | 未再测 | 42.1 | 33.4 | |
D二聚体(mg/L) | 来诊 | <0.15 | 0.21 | <0.15 | 3.62 |
最差 | 0.69 | 未再测 | 5.34 | 3.62 |
Table 5 Main laboratory results of patients with multiple organ dysfunction
化验 | 1号 | 7号 | 9号 | 10号 | |
---|---|---|---|---|---|
白细胞计数(×109/L) | 来诊 | 29.90 | 19.31 | 17.19 | 8.90 |
最差 | 29.90 | 19.31 | 35.49 | 30.14 | |
血小板计数(×109/L) | 来诊 | 199 | 485 | 539 | 333 |
最差 | 48 | 63 | 103 | 85 | |
肌酐(μmol/L) | 来诊 | 251 | 426 | 158 | 83 |
最差 | 364 | 426 | 259 | 233 | |
丙氨酸氨基转移酶(U/L) | 来诊 | 25 | 24 | 10 | 67 |
最差 | 250 | 5 350 | 323 | 71 | |
天冬氨酸氨基转移酶(U/L) | 来诊 | 33 | 28 | 23 | 61 |
最差 | 850 | 10 480 | 548 | 110 | |
总胆红素(μmol/L) | 来诊 | 8.8 | 9.4 | 15.5 | 10.4 |
最差 | 22.4 | 87.9 | 46.8 | 44.2 | |
肌钙蛋白I(μg/L) | 来诊 | <0.010 | <0.010 | 3.200 | 0.024 |
最差 | 3.200 | 12.000 | 19.000 | 0.032 | |
肌酸激酶(U/L) | 来诊 | 43 | 55 | 167 | 34 |
最差 | >16 000 | 13 934 | 24 101 | 2 242 | |
葡萄糖(mmol/L) | 来诊 | 15.4 | 5.6 | 8.1 | 24.0 |
最差 | 36.1 | 34.3 | 19.5 | 24.0 | |
pH值 | 来诊 | 7.32 | 7.05 | 7.53 | 7.48 |
最差 | 7.06 | 6.80 | 7.07 | 7.23 | |
脂肪酶(U/L) | 来诊 | 136 | 343 | 62 | 80 |
最差 | >2 000 | >2 000 | 929 | 431 | |
淀粉酶(U/L) | 来诊 | 89 | 70 | 135 | 57 |
最差 | 642 | 559 | 276 | 351 | |
凝血酶原时间(s) | 来诊 | 11.3 | 14.3 | 10.9 | 14.9 |
最差 | 12.9 | 未再测 | 15.0 | 15.4 | |
凝血酶原活动度(%) | 来诊 | 88 | 65 | 96 | 61 |
最差 | 67 | 未再测 | 51 | 59 | |
活化部分凝血活酶(s) | 来诊 | 26.6 | 31.6 | 34.5 | 100.7 |
最差 | 182.3 | 未再测 | 62.8 | 206.4 | |
纤维蛋白降解产物(mg/L) | 来诊 | <2.5 | <2.5 | <2.5 | 23.4 |
最差 | 6.1 | 未再测 | 42.1 | 33.4 | |
D二聚体(mg/L) | 来诊 | <0.15 | 0.21 | <0.15 | 3.62 |
最差 | 0.69 | 未再测 | 5.34 | 3.62 |
序号 | 洗胃 | 活性炭 | 导泻 | 补液 | 升压药 | 钙剂 | 高剂量胰岛素 | 脂肪乳 | 阿托品 | 临时起搏 | 心肺复苏 | 气管插管 | ECMO | 血液净化 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | +a | - | - | + | + | + | + | + | - | - | + | + | + | + |
2 | + | + | - | + | + | + | + | + | - | - | - | - | - | + |
3 | - | - | - | + | - | - | - | - | - | - | - | - | - | - |
4 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
5 | +a | - | - | + | + | + | + | - | - | - | - | - | - | - |
6 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
7 | + | + | + | + | + | + | + | + | + | - | + | + | + | + |
8 | + | - | - | + | + | + | + | + | - | - | - | - | - | - |
9 | + | - | - | + | + | + | + | - | - | - | + | + | + | + |
10 | + | + | + | + | + | + | + | + | + | + | - | + | + | + |
11 | + | - | - | + | + | + | + | + | - | - | - | + | - | + |
Table 6 Therapeutic measures for patients
序号 | 洗胃 | 活性炭 | 导泻 | 补液 | 升压药 | 钙剂 | 高剂量胰岛素 | 脂肪乳 | 阿托品 | 临时起搏 | 心肺复苏 | 气管插管 | ECMO | 血液净化 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | +a | - | - | + | + | + | + | + | - | - | + | + | + | + |
2 | + | + | - | + | + | + | + | + | - | - | - | - | - | + |
3 | - | - | - | + | - | - | - | - | - | - | - | - | - | - |
4 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
5 | +a | - | - | + | + | + | + | - | - | - | - | - | - | - |
6 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
7 | + | + | + | + | + | + | + | + | + | - | + | + | + | + |
8 | + | - | - | + | + | + | + | + | - | - | - | - | - | - |
9 | + | - | - | + | + | + | + | - | - | - | + | + | + | + |
10 | + | + | + | + | + | + | + | + | + | + | - | + | + | + |
11 | + | - | - | + | + | + | + | + | - | - | - | + | - | + |
序号 | 血液灌流 | CVVH | 血液灌流+CVVH | 血浆置换 |
---|---|---|---|---|
1 | 1 | 2 | 2 | 3 |
2 | 7 | — | — | — |
7 | 2 | 3 | 2 | — |
9 | 3 | 6 | — | — |
10 | 6 | 8 | — | 1 |
11 | 3 | — | — | — |
Table 7 Methods and times of blood purification
序号 | 血液灌流 | CVVH | 血液灌流+CVVH | 血浆置换 |
---|---|---|---|---|
1 | 1 | 2 | 2 | 3 |
2 | 7 | — | — | — |
7 | 2 | 3 | 2 | — |
9 | 3 | 6 | — | — |
10 | 6 | 8 | — | 1 |
11 | 3 | — | — | — |
序号 | 血液灌流前 | 血液灌流后 | 下降比例(%) | 血浆置换前 | 血浆置换后 | 下降比例(%) |
---|---|---|---|---|---|---|
1 | 氨氯地平890 μg/L | 氨氯地平785 μg/L | 11.80 | 氨氯地平785 μg/L | 氨氯地平658 μg/L | 16.18 |
2 | 氨氯地平219.7 μg/L | 氨氯地平198.9 μg/L | 9.47 | — | — | — |
7 | 氨氯地平39 μg/L;硝苯地平0.10 mg/L | 氨氯地平31 μg/L;硝苯地平0.06 mg/L | 20.51;40.00 | — | — | — |
9 | 硝苯地平1.1 mg/L | 硝苯地平0.4 mg/L | 63.64 | — | — | — |
10 | 维拉帕米1.5 mg/L | 维拉帕米1.1 mg/L | 26.67 | 维拉帕米1.1 mg/L | 维拉帕米1.0 mg/L | 9.09 |
11 | 硝苯地平4.8 mg/L | 硝苯地平1.8 mg/L | 62.50 | — | — | — |
Table 8 The plasma concentration of patients before and after the first blood purification
序号 | 血液灌流前 | 血液灌流后 | 下降比例(%) | 血浆置换前 | 血浆置换后 | 下降比例(%) |
---|---|---|---|---|---|---|
1 | 氨氯地平890 μg/L | 氨氯地平785 μg/L | 11.80 | 氨氯地平785 μg/L | 氨氯地平658 μg/L | 16.18 |
2 | 氨氯地平219.7 μg/L | 氨氯地平198.9 μg/L | 9.47 | — | — | — |
7 | 氨氯地平39 μg/L;硝苯地平0.10 mg/L | 氨氯地平31 μg/L;硝苯地平0.06 mg/L | 20.51;40.00 | — | — | — |
9 | 硝苯地平1.1 mg/L | 硝苯地平0.4 mg/L | 63.64 | — | — | — |
10 | 维拉帕米1.5 mg/L | 维拉帕米1.1 mg/L | 26.67 | 维拉帕米1.1 mg/L | 维拉帕米1.0 mg/L | 9.09 |
11 | 硝苯地平4.8 mg/L | 硝苯地平1.8 mg/L | 62.50 | — | — | — |
序号 | 入院24 h APACHE Ⅱ评分(分) | 入院PSS评分(分) | 出院PSS评分(分) | 入院GCS评分(分) | 出院GCS评分(分) | 住院天数(d) | 出院时是否存活 | 入院到血流动力学稳定时间(h) |
---|---|---|---|---|---|---|---|---|
1 | 27 | 3 | 4 | 15 | — | 4 | 死亡 | — |
2 | 8 | 3 | 3 | 15 | 15 | 6 | 存活 | 92 |
3 | 5 | 2 | 2 | 15 | 15 | 1 | 存活 | 1 |
4 | 5 | 1 | 1 | 15 | 15 | 1 | 存活 | — |
5 | 9 | 3 | 3 | 15 | 15 | 7 | 存活 | 5 |
6 | 10 | 1 | 1 | 15 | 15 | 3 | 存活 | — |
7 | 43 | 3 | 4 | 15 | — | 3 | 死亡 | — |
8 | 7 | 3 | 3 | 15 | 15 | 4 | 存活 | 47 |
9 | 37 | 3 | 3 | 15 | 15 | 32 | 存活 | 50 |
10 | 32 | 3 | 3 | 9 | 15 | 20 | 存活 | 117 |
11 | 18 | 3 | 3 | 15 | 15 | 4 | 存活 | 97 |
Table 9 The clinical score at admission and discharge,hospitalization days and prognosis of patients
序号 | 入院24 h APACHE Ⅱ评分(分) | 入院PSS评分(分) | 出院PSS评分(分) | 入院GCS评分(分) | 出院GCS评分(分) | 住院天数(d) | 出院时是否存活 | 入院到血流动力学稳定时间(h) |
---|---|---|---|---|---|---|---|---|
1 | 27 | 3 | 4 | 15 | — | 4 | 死亡 | — |
2 | 8 | 3 | 3 | 15 | 15 | 6 | 存活 | 92 |
3 | 5 | 2 | 2 | 15 | 15 | 1 | 存活 | 1 |
4 | 5 | 1 | 1 | 15 | 15 | 1 | 存活 | — |
5 | 9 | 3 | 3 | 15 | 15 | 7 | 存活 | 5 |
6 | 10 | 1 | 1 | 15 | 15 | 3 | 存活 | — |
7 | 43 | 3 | 4 | 15 | — | 3 | 死亡 | — |
8 | 7 | 3 | 3 | 15 | 15 | 4 | 存活 | 47 |
9 | 37 | 3 | 3 | 15 | 15 | 32 | 存活 | 50 |
10 | 32 | 3 | 3 | 9 | 15 | 20 | 存活 | 117 |
11 | 18 | 3 | 3 | 15 | 15 | 4 | 存活 | 97 |
[1] |
|
[2] | |
[3] |
白京京,张伟丽,王璐,等. 北京市基层医疗卫生机构降压药物使用情况及合理性分析[J]. 中华心血管病杂志,2021,49(10):993-999. DOI:10.3760/cma.j.cn112148-20201231-01022.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
心肺复苏后昏迷患者早期神经功能预后评估专家共识组. 心肺复苏后昏迷患者早期神经功能预后评估专家共识[J]. 中华急诊医学杂志,2019,28(2):156-162. DOI:10.3760/cma.j.issn.1671-0282.2019.02.006.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
赵力,王晓冰,朱彦,等. 大鼠急性脑缺血-再灌注损伤及氨氯地平保护作用的研究[J]. 高血压杂志,1997,5(S1):23-26. DOI:10.16439/j.cnki.1673-7245.1997.s1.008.
|
[22] |
郭阳,张培东,谭盛. 左旋氨氯地平对局灶性脑缺血小鼠模型脑梗死体积的影响[J]. 今日药学,2014,24(1):4-6.
|
[23] |
|
[24] |
吴彼得,陈珊莹,许向农,等. 系列血液净化治疗急性重症中毒的疗效观察[J]. 中国全科医学,2011,14(20):2337-2339. DOI:10.3969/j.issn.1007-9572.2011.20.042.
|
[25] |
|
[26] |
何怀武,刘大为,柴文昭,等. 血浆置换抢救难治重症氨氯地平过量中毒一例[J]. 中华医学杂志,2010,90(5):359-360. DOI:10.3760/cma.j.issn.0376-2491.2010.05.019.
|
[27] |
|
[28] |
穆宇航,李星亮,逄利. 硝苯地平中毒致麻痹性肠梗阻一例[J]. 中华劳动卫生职业病杂志,2021,39(12):952-953. DOI:10.3760/cma.j.cn121094-20210129-00062.
|
[29] |
周榆然,胡系意,袁策,等. 不同评分系统对急性中毒预后评估价值的比较[J]. 中华劳动卫生职业病杂志,2018,36(11):808-812. DOI:10.3760/cma.j.issn.1001-9391.2018.11.002.
|
[30] |
|
[1] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[2] | MIAO Guangrui, PANG Shuo, ZHOU Yuanhang, DUAN Mingxuan, BAI Linpeng, ZHANG Qingyang, ZHAO Xiaoyan, DONG Jianzeng. Short-term Prognostic Value of Early Fluid Balance and Lactate Clearance in Patients with Acute Myocardial Infarction Combined with Cardiogenic Shock Treated with Extracorporeal Membrane Oxygenation [J]. Chinese General Practice, 2023, 26(27): 3397-3402. |
[3] | Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219. |
[4] | DING Jing, MENG Zhuocheng, ZHANG Yan, CUI Xiaohua, LIU Jiarui, HE Jiao, ZHANG Yang, LI Yajuan, YANG Liu. Retrospective Analysis of 2 992 Times of Therapeutic Drug Monitoring of Valproic Acid from 2019 to 2021 [J]. Chinese General Practice, 2023, 26(23): 2923-2929. |
[5] | XU Wei, XU Jiyuan, LI Maoqin, LU Fei, CHENG Shuli. Predictive Value of Color Doppler Ultrasound for Acute Kidney Injury in Patients with Septic Shock [J]. Chinese General Practice, 2023, 26(09): 1104-1111. |
[6] | CHU Xiaoting, YANG Xiaoming, WAN Qiuping, ZHANG Guohui, XIONG Jianjing, FANG Jialie. Trend Analysis of Life Expectancy and Disease Spectrum in Residents of Jing'an District in Shanghai, 2016-2021 [J]. Chinese General Practice, 2022, 25(36): 4561-4566. |
[7] | Ziao RUI, Dongpu DAI, Yingying GUO, Shuo PANG, Yuanhang ZHOU, Yang DU, Xiaoyan ZHAO, Jianzeng DONG. Efficacy and Related Inflencing Factors of Intra-aortic Balloon Counterpulsation Combined with Extracorporeal Membrane Oxygenation in Patients with Acute Myocardial Infarction and Cardiogenic Shock [J]. Chinese General Practice, 2022, 25(21): 2597-2604. |
[8] |
GAN Junying, XU Heping, WU Kaifang, CHEN Yunmei, YE Xiaojuan.
Predictive Value of Age Shock Index for
Adverse Outcomes in Patients with Acute Gastrointestinal Bleeding
|
[9] |
FAN Guihong, HE Jun, PANG Gaofeng, LI Chen, JIANG Lushan, FANG Huimin, WANG Zhou.
Modified Electroconvulsive Therapy in Patients with Schizophrenia:Curative Effect and Responses of Neurotransmitters in Brain and Different Brain Regions [J]. Chinese General Practice, 2022, 25(03): 325-330. |
[10] | WANG Yueyue,XU Qixia. YEARS Algorithm:a New Diagnostic Strategy for Suspected Pulmonary Embolism [J]. Chinese General Practice, 2021, 24(26): 3383-3386. |
[11] | YU Jiangquan,ZHENG Ruiqiang,ZHU Jin,ZHAO Yuan,YANG Penglei. Velocity Time Integral Guides Fluid Therapy for COPD Patients with Septic Shock:a Clinical Study [J]. Chinese General Practice, 2021, 24(23): 2945-2949. |
[12] | ZHAO Hong,GE Hongxia,MA Qingbian,AN Yuping,GUO Zhiguo. Clinical Study of Characteristics of Acute Poisoning Caused by Difenidol Hydrochloride [J]. Chinese General Practice, 2021, 24(23): 2940-2944. |
[13] | XU Meixian,LIU Gang,CAO Lijing,SHI Xiaona,SUN Hui,LI June. The Main Early Clinical Features of Kawasaki Disease Shock Syndrome and Septic Shock in Children:a Comparative Study [J]. Chinese General Practice, 2020, 23(30): 3812-3816. |
[14] | ZHOU Shuqing,SHEN Tao. Risk Factors and Prognostic Impact of New-onset Atrial Fibrillation in Patients with Sepsis [J]. Chinese General Practice, 2019, 22(24): 2929-2932. |
[15] | MA Guoying,HAN Yongyan,YANG Junli,SUN Wei,WANG Weizhan. Associations of Neutrophil-to-lymphocyte Ratio and Procalcitonin with the Prognosis in Patients with Acute Severe Carbon Monoxide Poisoning and Hospital-acquired Pneumonia [J]. Chinese General Practice, 2019, 22(20): 2426-2430. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||